LPL and metabolic syndrome: SLKDT extracts upregulated mRNA expressions of PPAR‐α, LPL, CPT1, and CYP7A1 and downregulated mRNA expressions of PPAR‐γ and C/EBP‐α, which reduced adipocyte differentiation and fat accumulation, promoted fat oxidation, and improved dyslipidemia.